glp 1 clinical pearls Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System JDD Buzz Series | GLP-1

#HealthcareInnovation #FDA #PatientAccess To view or add a comment, sign in Biosimilars: Making Healthcare Better 70 FDA approvals, 49 already in use Saved over $36 billion since 2015 Helping more patients get treatment Can be swapped at the pharmacy (interchangeability) FDA focusing on strong testing to ensure safety & quality Easy tools like the FDA Purple Book for doctors & patients Biosimilars = safe, effective & affordable Thanks to Dr

These advanced treatments have shown incredible results in helping patients lose weight safely and effectively

A realistic weight loss timeline on Zepbound or Wegovy involves a gradual ramp-up in dose over the first 4-5 months, followed by a period of consistent loss

doi:10.1056/NEJMoa1607141 7

Theory of receptor cross-linking by ligands bearing two chemically identical functional group